Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) EBIT Margin (2024 - 2025)

Historic EBIT Margin for Xilio Therapeutics (XLO) over the last 2 years, with Q3 2025 value amounting to 10.12%.

  • Xilio Therapeutics' EBIT Margin rose 6422000.0% to 10.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 137.64%, marking a year-over-year change of. This contributed to the annual value of 954.95% for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Xilio Therapeutics' EBIT Margin stood at 10.12%, which was up 6422000.0% from 177.71% recorded in Q2 2025.
  • Xilio Therapeutics' EBIT Margin's 5-year high stood at 10.12% during Q3 2025, with a 5-year trough of 790.55% in Q4 2024.